Will Prime Medicine stock go up?

According to Danelfin AI, Prime Medicine has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.99%) is -1.83% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Prime Medicine stock?

The Prime Medicine target price is $3.89 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Prime Medicine stock right now?

Prime Medicine has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (48.99%) is -1.83% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Prime Medicine stock is a good buy .

Is Prime Medicine undervalued right now?

Based on analysts, the average price target downside for Prime Medicine is 0.00% (1Y). According to Danelfin AI, Prime Medicine has today an AI Score of 4/10 (Hold Rating).

What was the price range of Prime Medicine stock over the past 12 months?

The Prime Medicine stock price range over the past 12 months has been $2.07 - $6.67.

What is going on with Prime Medicine stock in the last 3 months?

The Prime Medicine stock performance in the last quarter has been +14.74%.

Does Prime Medicine offer dividend payments?

No, Prime Medicine does not currently pay dividends.

What is the current market capitalization of Prime Medicine?

Prime Medicine's market cap is $698.99M, as of 2026-07-03 08:00.

Prime Medicine Inc (PRME) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

PRME AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+1.60%
How the stock is priced relative to its fundamentals
Earnings Quality+1.17%
Stability and reliability of reported earnings
Size & Liquidity+0.29%
Company size and trading liquidity

Momentum-3.34%
Direction and strength of recent price movements
Volatility-0.97%
How much the stock price tends to fluctuate
Profitability-0.55%
Profitability and operating efficiency metrics
Sentiment-0.03%
How analysts and the market view the stock

PRME probability advantage of beating the market (3M):

-1.83%

AI Score

Hold

Prime Medicine (PRME) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -1.83% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of PRME (48.99%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
PRME probability advantage of beating the market (3M)-1.83%
PRME probability of beating the market (3M)48.99%

PRME probability advantage of beating the market (3M): -1.83%

The AI-powered overall analysis of Prime Medicine (PRME) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of PRME:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.98%
Technical	Chart Pattern (504d)	figure_83	N/A	-1.95%
Fundamental	Operating Cash Flow (Qtr Discrete)	-42.71	N/A	+1.17%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.00%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.75%
Technical	Maximum Volatility	9.19%		-0.66%
Technical	Distance from KAMA (20d)	0.22%		-0.63%
Sentiment	Analyst Lowest Price Upside	-0.78%	N/A	-0.57%
Technical	Performance (YTD)	0.12%		-0.47%
Technical	Chart Pattern (252d)	figure_16	N/A	-0.47%
Fundamental	Upgrade to unlock			-0.47%
Sentiment	Upgrade to unlock			+0.37%
Fundamental	Upgrade to unlock			+0.35%
Technical	Upgrade to unlock			-0.31%
Fundamental	Upgrade to unlock			-0.30%

Rest of Alpha Signals: +0.38%

PRME probability advantage of beating the market (3M)Total:-1.83%
PRME AI Score

Significant changes Vs previous day

PRME Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$3.89
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

PRME Proven Hold Signal & Price Forecast

This is the price chart for PRME from January 2, 2026 until today. The chart indicates, in yellow, the 64 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

PRME Average Past Performance & Win Rate

Three months after its 577 Hold signals since July 2026, PRME had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

577 Past PRME Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-41.73%
Average Alpha				-63.06%
Win Rate (% Positive Perf.)				14.94%
% Positive Alpha				12.20%

PRME Frequently Asked Questions

Will Prime Medicine stock go up?
According to Danelfin AI, Prime Medicine has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.99%) is -1.83% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Prime Medicine stock?
Is it a good time to buy, sell, or hold Prime Medicine stock right now?
Is Prime Medicine undervalued right now?
What was the price range of Prime Medicine stock over the past 12 months?
What is going on with Prime Medicine stock in the last 3 months?
Does Prime Medicine offer dividend payments?
What is the current market capitalization of Prime Medicine?

Prime Medicine Inc Company Profile

Prime Medicine Inc., a biotechnology firm, specializes in providing solutions for an array of diseases through its groundbreaking gene editing technology. The business has developed Prime Editors that include a Prime Editor protein—a unique blend of a Cas protein and reverse transcriptase enzyme. This product houses a pegRNA that guides the Prime Editor to a specific genomic location, accomplishing the needed alteration to the target DNA sequence.

The company actively collaborates with Cimeio Therapeutics, undertaking significant research to create Prime Edited Shielded-Cell & Immunotherapy Pairs. These innovative pairs aim to combat genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome—demonstrating the organization's commitment towards health improvement.

Established in 2019, Prime Medicine Inc. presides over its operations from its main office based in Cambridge, Massachusetts. Combining cutting-edge technology with advanced biochemical understanding, the company endeavors to transform the field of genetic medicine.

Sector:
Country:United States
Industry:
Address:60 First St., Cambridge
Employees:146
Website:primemedicine.com

Pros

Proprietary prime editing technology platform

Broad applicability across genetic disease types

Potential for high precision gene correction

Platform technology enabling multiple programs

Avoidance of double-strand DNA breaks

Cons

Extensive capital requirements for research and development

Prolonged clinical development and regulatory pathways

Uncertainty regarding long-term clinical outcomes

Intense competition from alternative gene editing methods

Exposure to complex intellectual property disputes

Company	AI Score	Compare
EDITEditas Medicine Inc
MGXMetagenomi Therapeutics Inc
DTILPrecision BioSciences Inc
BEAMBeam Therapeutics Inc
GNPXGenprex Inc

Company	AI Score	Compare
EDITEditas Medicine Inc
MGXMetagenomi Therapeutics Inc
DTILPrecision BioSciences Inc
BEAMBeam Therapeutics Inc
GNPXGenprex Inc

PRME Stock AI Analysis